The FDA approval of Xocova marks a new front in the antiviral arsenal, shifting from treatment to prevention …
The FDA approval of Xocova marks a new front in the antiviral arsenal, shifting from treatment to prevention …
The stealth-mode startup emerges with a pipeline targeting focal epilepsy, schizophrenia, tinnitus, and reversible encephalopathy — all acquired …
The U.S. Food and Drug Administration has approved VEPPANU (vepdegestrant), marking a significant milestone as the first PROTAC …
The global Alzheimer’s disease drug development pipeline has reached an unprecedented scale in 2026, with 192 active clinical …
In the VERIFY study rusfertide demonstrated both safety and efficacy in reducing phlebotomy dependence for patients with polycythemia …
A new international trial aims to confirm the benefit of adding masitinib to chemotherapy in men with metastatic …
New option opens for patients who have exhausted several therapies in their fight against relapsed or refractory multiple …
Company Overview and Focus Biodexa Pharmaceuticals PLC, a clinical-stage biotechnology company dedicated to developing innovative treatments for diseases …
Continued program expansion strengthens potential to deliver an all-oral, pan-genotypic next-generation HCV therapy.
Dual GLP-1 and GIP receptor agonist VK2735 moves into pivotal trials targeting robust weight loss and glycemic control …
Already a subscriber? Log in